Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. - Wikidata - awgldk - TriplyDB

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

http://www.wikidata.org/entity/Q44000915

about

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics Mechanisms of viral entry: sneaking in the front door HIV-1 entry inhibitors: an overview Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Role of Marine Natural Products in the Genesis of Antiviral Agents HIV-1 entry inhibitors: recent development and clinical use In vivo binding and retention of CD4-specific DARPin 57.2 in macaques Tetraspanins in viral infections: a fundamental role in viral biology?Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody HIV entry inhibitors: mechanisms of action and resistance pathways Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.HIV entry inhibitors and their potential in HIV therapy Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).The critical need for alternative antiretroviral formulations, and obstacles to their development.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.HIV-1 antiretroviral drug therapy.The brightening future of HIV therapeutics.Monoclonal antibody-based candidate therapeutics against HIV type 1.A pathophysiological approach to antiretroviral therapy.Clinical experience with therapeutic AIDS vaccines.HIV entry inhibitors: a new generation of antiretroviral drugs.Antibody-based inhibitors of HIV infection.Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets Novel inhibitors of the early steps of the HIV-1 life cycle.Next-generation oral preexposure prophylaxis: beyond tenofovir Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1 Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.Novel compounds for the treatment of HIV type-1 infection.Maraviroc: a new CCR5 antagonist.Lessons learned from HIV vaccine clinical efficacy trials.

P2860

Q21090521-AB2EF9E8-D0AB-4CFD-9DE5-7681FAA74C4A Q22252690-6DA41036-3312-43D7-A5C2-61E45AD8D412 Q24645525-4E376A58-AFEC-41D6-B59D-42362DAEC620 Q24645675-94521FD7-C221-4B94-84A8-1B3E7461EB05 Q26796360-746FF65C-756C-42C7-9696-94DD863D8890 Q27003887-A5F99B51-3166-4070-85CA-8A07AFB7D721 Q27320871-47C53EE9-FF92-4776-A9B1-69BE98AFA8EA Q27470936-256B016C-AF98-4F6E-89C8-938C2CD25BDE Q27666197-F5D46450-324F-433A-9C69-C42EE6275F43 Q28296162-A5D8D11B-DC30-412A-88CA-6E0C32592536 Q33223969-3EBAD3F5-B6B9-4F31-A64A-E460CA991198 Q33810849-E1E32D80-D4F3-4BC2-859D-E48D6587EEF0 Q34174815-4AE42884-C48B-416A-B345-EF3A63D01EE2 Q34473072-C9183525-7535-41A2-BFB9-FA312664FF4E Q34536782-F12F3AF8-91C9-428D-BCD0-45528B3F30DD Q34536817-5CC1BE9F-9FC9-47B4-A14E-495C5DF48FA4 Q34595921-32D1D53B-BBF5-4F80-931F-616B4B623368 Q34648499-B6B38053-42DC-45B9-8893-02BE7200BDA2 Q34680667-B0483D8F-AEF8-428F-8805-3F6C7B860108 Q35164438-3CF5B711-8ECA-4BEA-B5EE-0109DE3821CC Q35677620-A0C0A32E-B506-4FCB-A8BD-FE7ADEFAD6D5 Q35784750-FD7A14F8-A8EA-460A-8BCB-341A56794114 Q35853012-D03A363A-8EF3-46F1-9D7E-3B0B95AD85A6 Q35873262-7D1C11A4-3EF2-4377-AD9B-9477A5A5C6C8 Q35904501-3F89F497-95A2-4780-B263-697BEA2A0BEB Q35917460-0F78E69D-4460-4D27-8486-B9927E0880C2 Q36198648-97614F0C-8DDD-4170-90AC-8744AE8BC578 Q36262437-352F5E64-B013-4238-9C09-D659465AF253 Q36446952-634A42DF-7217-4F7D-A33E-DA1F181B60A7 Q36631937-335288FF-29C7-429F-A53E-4FE22220219B Q36677383-9A4D5A70-1A9C-4544-ACB4-02FF168E088E Q37067126-1A84D9A5-FAF2-45A8-B001-F5D9EE5D1719 Q37088591-DB0BF0C5-593D-4660-A5B6-62FDDFE796FB Q37102101-50248DA5-4715-49BE-A2BA-70DBD1E9835F Q37103977-E22B1AB5-1530-4208-A030-5BC5589106DD Q37302902-8EEF964B-FC87-42A6-8DF5-D427EDA3E682 Q37388409-73DC91DB-2FB4-453C-97B5-916A7AD4C04F Q37502492-43F65484-DB82-41E0-90F4-3BC829D1AFA7 Q37557671-D2C18157-A853-4668-B456-D7EF26E0E2AF Q37724091-FE59077A-733A-4B0C-ACE9-4C677AA32C36

P2860

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

http://www.wikidata.org/entity/Q44000915

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Antiretroviral activity of the ...... ents infected with HIV type 1.

@en

Antiretroviral activity of the ...... ents infected with HIV type 1.

@nl

type

label

Antiretroviral activity of the ...... ents infected with HIV type 1.

@en

Antiretroviral activity of the ...... ents infected with HIV type 1.

@nl

prefLabel

Antiretroviral activity of the ...... ents infected with HIV type 1.

@en

Antiretroviral activity of the ...... ents infected with HIV type 1.

@nl

P1433

Q44000915-448D4898-2C65-42C9-9EB4-61E702340B7F

P1476

Q44000915-600EB19C-C479-4901-BF43-B92830767EEE

P2093

Q44000915-0F6892D5-D00C-454B-ACFA-20D9B2D5EF66

Q44000915-3F33A30C-DF92-4B1E-BB7C-4228FC4D0506

Q44000915-57767EBA-76E3-49EF-B41F-E03B28A73C6C

Q44000915-5813146E-A309-4028-84A9-05E92EB8DCB0

Q44000915-8750A126-929F-4E82-824E-9B837EBCF7DE

Q44000915-8938E704-EA91-4B3E-8297-DC77063288BD

Q44000915-8DB2AE6A-59AE-4217-89B1-DF8ACCBE0306

Q44000915-A08EF285-13CF-49F4-9574-8A8A588C3884

Q44000915-B3245CCC-8B9B-4F20-BE8C-007515F5E7DD

Q44000915-D71ED218-0FB0-44CB-ACF9-A946A99032F4

P304

Q44000915-641FF77C-8719-4613-B8CC-BB5B3B21FB6E

P31

Q44000915-F6C05CBE-22D2-4B0F-974D-FF56F063F1A9

P356

Q44000915-3646CA7E-91D6-40E0-8CD6-85B3988A387D

P407

Q44000915-EEBF0833-27EF-43E6-93DF-4807C06F2162

P433

Q44000915-1C3D96B4-19BE-4AF6-80FE-22586D80CF18

P478

Q44000915-5F78CA82-1625-4707-9E2A-9F359C5C8AE9

P577

Q44000915-55301D65-F332-4040-81E0-8D1FB4592D91

P5875

Q44000915-AE061EE6-C09B-435F-8C70-4761045C4F34

P698

Q44000915-511F0B0F-E731-4E5D-8F29-F504E47C8629

P921

Q44000915-BB9D6657-015A-4BBA-A2E4-D9FC93C31F6E

Q44000915-E728E575-E490-4155-B105-7CB8F68EEB4D

P356

P1433

The Journal of Infectious Diseases

P1476

Antiretroviral activity of the ...... ents infected with HIV type 1.

@en

P2093

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Eliot Godofsky

http://www.w3.org/2001/XMLSchema#string

Frances Haas

http://www.w3.org/2001/XMLSchema#string

Jeffrey Jacobson

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Larson

http://www.w3.org/2001/XMLSchema#string

Keith A Reimann

http://www.w3.org/2001/XMLSchema#string

Patrice O Yarbough

http://www.w3.org/2001/XMLSchema#string

Valentin Curt

http://www.w3.org/2001/XMLSchema#string

William G Powderly

http://www.w3.org/2001/XMLSchema#string

P304

286-291

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/380802

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8919985

http://www.w3.org/2001/XMLSchema#string

P698

14722894

http://www.w3.org/2001/XMLSchema#string

P921